Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Reizdarmsyndrom – Diagnostik und Therapie

Irritable bowel syndrome—diagnostics and therapy

  • 428 Accesses

  • 2 Citations

Zusammenfassung

Bis zu 25 % aller gastroenterologischen Patienten leiden unter einem Reizdarmsyndrom (RDS). Bei Neudiagnose eines RDS sind eine fundierte und zielgerichtete Diagnostik entscheidend für den weiteren klinischen Verlauf. Nach Diagnosestellung erbringen erneute Abklärungen, insbesondere repetitive endoskopische Untersuchungen, jedoch praktisch nie zusätzliche Erkenntnisse. Die medikamentöse Therapie ist individuell an den Symptomen des Patienten auszurichten. Nichtmedikamentöse und alternative Therapieverfahren können dabei eine wirksame Ergänzung darstellen.

Abstract

Up to 25 % of gastroenterology outpatients complain of symptoms attributable to irritable bowel syndrome (IBS). A well founded diagnosis of IBS is the key to subsequent successful treatment. To safely establish a diagnosis of IBS a panel of basic investigations to carefully exclude alternative diagnoses is warranted. Once the diagnosis of IBS is established repetition of examinations, especially repeat endoscopy should be avoided in the absence of new clinical information. Medical treatment should be tailored to individual symptoms. Non-medical forms of treatment including dietary changes, exercise and alternative forms of treatment, such as hypnotherapy can be effective supportive measures in IBS.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Akehurst R, Kaltenthaler E (2001) Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 48: 272–282

  2. 2.

    Bijkerk CJ, Wit NJ de, Muris JW et al (2009) Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 339: b3154

  3. 3.

    Black TP, Manolakis CS, Di Palma JA (2012) „Red flag“ evaluation yield in irritable bowel syndrome. J Gastrointestin Liver Dis 21: 153–156

  4. 4.

    Brandt LJ, Chey WD, Foxx-Orenstein AE et al (2009) An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104(Suppl 1): S1–S35

  5. 5.

    Brinkhaus B, Hentschel C, Von Keudell C et al (2005) Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol 40: 936–943

  6. 6.

    Chey WD, Drossman DA, Johanson JF et al (2012) Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 35: 587–599

  7. 7.

    Chey WD, Lembo AJ, Lavins BJ et al (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107: 1702–1712

  8. 8.

    Dang J, Ardila-Hani A, Amichai MM et al (2012) Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil 24: 853–e397

  9. 9.

    Di Palma JA, Herrera JL (2012) The role of effective clinician-patient communication in the management of irritable bowel syndrome and chronic constipation. J Clin Gastroenterol 46: 748–751

  10. 10.

    Drossman DA, Toner BB, Whitehead WE et al (2003) Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125: 19–31

  11. 11.

    Engsbro AL, Begtrup LM, Kjeldsen J et al (2013) Patients suspected of irritable bowel syndrome-cross-sectional study exploring the sensitivity of Rome III criteria in primary care. Am J Gastroenterol 108: 972–980

  12. 12.

    Ford AC, Chey WD, Talley NJ et al (2009) Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 169: 651–658

  13. 13.

    Ford AC, Talley NJ, Spiegel BM et al (2008) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337: a2313

  14. 14.

    Ford AC, Vandvik PO (2012) Irritable bowel syndrome. Clin Evid (Online)

  15. 15.

    Gibson PR, Shepherd SJ (2010) Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 25: 252–258

  16. 16.

    Halpert A, Dalton CB, Diamant NE et al (2005) Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 100: 664–671

  17. 17.

    Halpert A, Dalton CB, Palsson O et al (2007) What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol 102: 1972–1982

  18. 18.

    Halpin SJ, Ford AC (2012) Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 107: 1474–1482

  19. 19.

    Harvey RF, Salih SY, Read AE (1983) Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1: 632–634

  20. 20.

    Johannesson E, Simren M, Strid H et al (2011) Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 106: 915–922

  21. 21.

    Khan S, Chang L (2010) Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol 7: 565–581

  22. 22.

    Layer P, Andresen V, Pehl C et al (2011) Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 49: 237–293

  23. 23.

    Leeds JS, Hopper AD, Sidhu R et al (2010) Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol 8: 433–438

  24. 24.

    Leung WK, Wu JC, Liang SM et al (2006) Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol 101: 1574–1580

  25. 25.

    Madisch A, Holtmann G, Plein K et al (2004) Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19: 271–279

  26. 26.

    Manheimer E, Wieland LS, Cheng K et al (2012) Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 107: 835–847 (quiz 848)

  27. 27.

    Moser G, Tragner S, Gajowniczek EE et al (2013) Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 108: 602–609

  28. 28.

    Offner FA, Jao RV, Lewin KJ et al (1999) Collagenous colitis: a study of the distribution of morphological abnormalities and their histological detection. Hum Pathol 30: 451–457

  29. 29.

    Pan F, Zhang T, Zhang YH et al (2009) Effect of Tongxie Yaofang Granule in treating diarrhea-predominate irritable bowel syndrome. Chin J Integr Med 15: 216–219

  30. 30.

    Park MI, Camilleri M (2006) Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 18: 595–607

  31. 31.

    Pimentel M, Lembo A, Chey WD et al (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: 22–32

  32. 32.

    Poynard T, Regimbeau C, Benhamou Y (2001) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15: 355–361

  33. 33.

    Ruepert L, Quartero AO, Wit NJ de et al (2011) Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev: CD003460

  34. 34.

    Saito YA, Rey E, Almazar-Elder AE et al (2010) A randomized, double-blind, placebo-controlled trial of St John’s wort for treating irritable bowel syndrome. Am J Gastroenterol 105: 170–177

  35. 35.

    Shinozaki M, Kanazawa M, Kano M et al (2010) Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. Appl Psychophysiol Biofeedback 35: 189–198

  36. 36.

    Vahedi H, Merat S, Momtahen S et al (2008) Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 27: 678–684

  37. 37.

    Wang G, Li TQ, Wang L et al (2006) Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: a prospective, randomized, double-blind, placebo-controlled trial. Chin Med J (Engl) 119: 2114–2119

  38. 38.

    Wedlake L, A’Hern R, Russell D et al (2009) Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 30: 707–717

  39. 39.

    Whorwell PJ, Prior A, Faragher EB (1984) Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 2: 1232–1234

  40. 40.

    Yang J, Lee HR, Low K et al (2008) Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 53: 169–174

  41. 41.

    Yoon SL, Grundmann O, Koepp L et al (2011) Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Altern Med Rev 16: 134–151

Download references

Einhaltung der ethischen Richtlinien

Interessenkonflikt. Dr. Pohl ist als Berater für die Firma Almirall tätig. Er erhält Referentenhonorar von der Firma MSD und Kongressunterstützung von der Firma Roche Pharma (Schweiz). Dr. Heinrich gibt an, dass kein Interessenkonflikt besteht. Dr. Misselwitz erhält Referentenhonorar von der Firma MSD.

Author information

Correspondence to Dr. D. Pohl.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pohl, D., Heinrich, H. & Misselwitz, B. Reizdarmsyndrom – Diagnostik und Therapie. Gastroenterologe 8, 417–424 (2013). https://doi.org/10.1007/s11377-013-0783-1

Download citation

Schlüsselwörter

  • RDS/IBS
  • Obstipation
  • Diarrhö
  • Lebensstilveränderungen
  • FODMAPs

Keywords

  • Colonic diseases, functional
  • Constipation
  • Diarrhea
  • Lifestyle modifications
  • FODMAPs